ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 13 of 58
Up
JMBS 2020, 5(6): 95–101
https://doi.org/10.26693/jmbs05.06.095
Clinical Medicine

Effects of Ademetionine on Liver Fibrosis, Level of Pentraxin-3 and Metabolic Indicators in Patients with Comorbid Course of Non-alcoholic Liver Disease and Arterial Hypertension

Alexandrova T. N., Babak O. Ya.
Abstract

Nonalcoholic fatty liver disease is the most common liver disease in the world, showing a variety of histopathological findings ranging from simple steatosis to nonalcoholic steatohepatitis and cirrhosis. Patients with nonalcoholic fatty liver disease have the potential to develop fibrosis and cirrhosis leading to portal hypertension, liver decompensation, and even hepatocellular carcinoma. Nonalcoholic fatty liver disease can be differentiated from simple steatosis by liver biopsy and is diagnosed when all of the following three criteria are met: macrovesicular fatty change of hepatocytes, inflammatory cell infiltration, and ballooning degeneration of hepatocytes. Lipid accumulation in hepatocytes can lead to inflammation within them. Accordingly, significant fibrosis can cause cirrhosis over a period of 10-20 years, but the pathophysiology is not well understood yet. However, liver biopsy is invasive, has drawbacks such as sampling error and cost, and it is not applicable for all patients. Also, there was a greater interest in science and practical medicine in the use of non-invasive methods for diagnosing the stages of nonalcoholic fatty liver disease. Primed on clinical and scientific data, non-invasive markers of liver fibrosis have to be highly sensitive and specific in identifying the early stages of liver fibrosis. The purpose of the work was to determine the effect of S-adenosylmethionine (ademetionine) on the stage of liver fibrosis, the level of pentraxin-3, C-reactive protein and metabolic parameters in patients with comorbide course of non-alcoholic fatty liver disease and arterial hypertension. Results and discussion. On the 61st day from the start of ademetionine use, there was a tendency to a decrease in the number of patients with comorbid course of non-alcoholic fatty liver disease and arterial hypertension in the stage of liver fibrosis F1 and F2 and an increase in the F0 stage. In addition, a significant decrease in the indicators of systemic inflammation (pentraxin-3, C-reactive protein) was achieved (p <0.05). The patients with comorbid course of non-alcoholic fatty liver disease and arterial hypertension also had a statistically significant (p <0.05) positive dynamics of hepatocyte cytolysis indicators was achieved in comparison with those before treatment and with the control group (p <0.05), as well as the lipid profile (p <0.05). Conclusion. The study showed that using ademetionine in patients with comorbid course of non-alcoholic fatty liver disease and arterial hypertension promoted regression of the stage of liver fibrosis, a significant decrease in the level of pentraxin-3, C-reactive protein, and an improvement in metabolic parameters. Appointment of ademetionine is an expedient method of treating patients with comorbid course of non-alcoholic fatty liver disease and arterial hypertension as a pathogenetic medicine with a pronounced antifibrotic, anti-inflammatory and cytoprotective effect

Keywords: nonalcoholic fatty liver disease, liver fibrosis, arterial hypertension, ademetionine, pentraxin-3

Full text: PDF (Ukr) 304K

References
  1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan; 15(1): 11-20. https://doi.org/10.1038/nrgastro.2017.109
  2. Pierantonelli I, Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Transplantation. 2019 Jan; 103(1): e1-e13. https://doi.org/10.1097/TP.0000000000002480
  3. Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019 Jan; 76(1): 99-128. https://doi.org/10.1007/s00018-018-2947-0
  4. Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009; 44(10): 1236-43. https://doi.org/10.1080/00365520903171284
  5. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006 Oct; 44(4): 865-73. https://doi.org/10.1002/hep.21327
  6. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005 Jan; 42(1): 132-8. https://doi.org/10.1016/j.jhep.2004.09.012
  7. Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018 Aug 14; 24(30): 3361-3373. https://doi.org/10.3748/wjg.v24.i30.3361
  8. Smith A, Baumgartner K, Bositis C. Cirrhosis: Diagnosis and Management. Am Fam Physician. 2019 Dec 15; 100(12): 759-770. PMID: 31845776
  9. Wiese S, Voiosu A, Hove JD, Danielsen KV, Voiosu T, Grønbaek H, et al. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy. Aliment Pharmacol Ther. 2020 Jul; 52(2): 340-350. https://doi.org/10.1111/apt.15812
  10. Lozano-Rosas MG, Chávez E, Velasco-Loyden G, Domínguez-López M, Martínez-Pérez L, Chagoya De Sánchez V. Diminished S-adenosylmethionine biosynthesis and its metabolism in a model of hepatocellular carcinoma is recuperated by an adenosine derivative. Cancer Biol Ther. 2020; 21(1): 81-94. https://doi.org/10.1080/15384047.2019.1665954
  11. Vergani L, Baldini F, Khalil M, Voci A, Putignano P, Miraglia N. New Perspectives of S-Adenosylmethionine (SAMe) Applications to Attenuate Fatty Acid-Induced Steatosis and Oxidative Stress in Hepatic and Endothelial Cells. Molecules. 2020 Sep 15; 25(18): 4237. https://doi.org/10.3390/molecules25184237
  12. Ornoy A, Becker M, Weinstein-Fudim L, Ergaz Z. S-Adenosine Methionine (SAMe) and Valproic Acid (VPA) as Epigenetic Modulators: Special Emphasis on their Interactions Affecting Nervous Tissue during Pregnancy. Int J Mol Sci. 2020 May 25; 21(10): 3721. https://doi.org/10.3390/ijms21103721
  13. Ouyang Y, Wu Q, Li J, Sun S, Sun S. S-adenosylmethionine: A metabolite critical to the regulation of autophagy. Cell Prolif. 2020 Nov; 53(11): e12891. https://doi.org/10.1111/cpr.12891
  14. Maria Del Bas J, Rodríguez B, Puiggròs F, Mariné S, Rodríguez MA, Moriña D, et al. Hepatic accumulation of S-adenosylmethionine in hamsters with non-alcoholic fatty liver disease associated with metabolic syndrome under selenium and vitamin E deficiency. Clin Sci (Lond). 2019 Feb 5;133(3): 409-423. https://doi.org/10.1042/CS20171039
  15. Antoniv A, Antofiychuk N, Danylyshina T, Trefanenko I, Shuper V. Clinical efficacy of s-adenosylmethionine in patients with non-alcoholic steatohepatitis and chronic kidney disease i-ii stage. Georgian Med News. 2017 Dec; 273: 31-36. PMID: 29328026
  16. Wunsch E, Raszeja-Wyszomirska J, Barbier O, Milkiewicz M, Krawczyk M, Milkiewicz P. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. J Gastrointestin Liver Dis. 2018 Sep; 27(3): 273-279. https://doi.org/10.15403/jgld.2014.1121.273.icz
  17. Morikawa S, Takabe W, Mataki C, Wada Y, Izumi A, Saito Y, et al. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb. 2004; 11: 62-72. https://doi.org/10.5551/jat.11.62
  18. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64: 1388-402. https://doi.org/10.1016/j.jhep.2015.11.004
  19. Zhang X, Wong GL, Wong VW. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020 Apr; 26(2): 128-141. PMID: 31696690. PMCID: PMC7160347. https://doi.org/10.3350/cmh.2019.0001n
  20. Serra-Burriel M, Graupera I, Torán P, Thiele M, Roulot D, Wai-Sun Wong V, et al; investigators of the LiverScreen Consortium. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol. 2019 Dec; 71(6): 1141-1151. https://doi.org/10.1016/j.jhep.2019.08.019
  21. Mora SI, García-Román J, Gómez-Ñañez I, García-Román R. Chronic liver diseases and the potential use of S-adenosyl-L-methionine as a hepatoprotector. Eur J Gastroenterol Hepatol. 2018 Aug; 30(8): 893-900. https://doi.org/10.1097/MEG.0000000000001141
  22. Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015 Jun; 240(6): 809-20. https://doi.org/10.1177/1535370215579161